The Lancet August 24, 2019

Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial

Gholamreza Roshandel, Masoud Khoshnia, Hossein Poustchi et al.

Bottom Line

In a rural Iranian population, a once-daily polypill containing aspirin, atorvastatin, hydrochlorothiazide, and enalapril or valsartan significantly reduced the risk of major cardiovascular events by 34% over 5 years compared to minimal care.

Key Findings

1. Over a 60-month follow-up, major cardiovascular events occurred in 5.9% of participants in the polypill group versus 8.8% in the minimal care group (adjusted HR 0.66; 95% CI 0.55-0.80).

2. The polypill was effective in both primary and secondary prevention, reducing the risk of major cardiovascular events by 39% in individuals without prior CVD and by 20% in those with a history of CVD.

3. Medication adherence was exceptionally high, with a median adherence rate of 80.5% in the polypill group.

4. The number needed to treat (NNT) to prevent one major cardiovascular event over 5 years was approximately 34.5.

5. There was no significant difference in the incidence of adverse events, including upper gastrointestinal bleeding or intracranial hemorrhage, between the two groups.

Study Design

Design

Cluster-Randomized Trial

Open-Label

Sample

6,838

Patients

Duration

60 mo

Median

Setting

Golestan province, Iran

Population Adults aged 50 to 75 years, with and without a history of cardiovascular disease, residing in rural areas and actively participating in the Golestan Cohort Study.

Intervention A once-daily fixed-dose combination polypill containing aspirin (81 mg), atorvastatin (20 mg), hydrochlorothiazide (12.5 mg), and enalapril (5 mg) (or valsartan 40 mg if enalapril caused cough), plus minimal care (healthy lifestyle education).

Comparator Minimal care alone, which consisted of non-pharmacological healthy lifestyle advice including diet, exercise, and smoking cessation counseling.

Outcome The occurrence of major cardiovascular events, defined as a composite of hospitalization for acute coronary syndrome, fatal myocardial infarction, sudden death, heart failure, coronary artery revascularization, and non-fatal or fatal stroke.

Study Limitations

• The open-label, pragmatic design could introduce performance bias, although hard clinical outcomes were centrally evaluated by blinded assessors.

• The trial was conducted in rural areas of a single province in Iran, which may limit generalizability to higher-income countries, urban settings, or populations with different baseline cardiovascular risk factor profiles.

• The fixed-dose regimen prevented individual titration, potentially resulting in suboptimal risk factor control for some participants.

• Participants were already enrolled in the Golestan Cohort Study, potentially exhibiting better health-seeking behaviors than the general population.

Clinical Significance

PolyIran provides landmark evidence that a low-cost, fixed-dose polypill strategy is highly effective and safe for reducing major cardiovascular events at the population level. The findings strongly support the implementation of polypills in preventative strategies, particularly in low- and middle-income countries, to cost-effectively reduce the global burden of cardiovascular morbidity and mortality.

Historical Context

The concept of a cardiovascular 'polypill' to simultaneously address multiple risk factors was first proposed by Wald and Law in 2003. While subsequent studies (such as UMPIRE and TIPS) demonstrated that polypills improved medication adherence and surrogate markers like blood pressure and lipid levels, the PolyIran trial was the first large-scale, long-term pragmatic trial to definitively demonstrate a reduction in hard clinical cardiovascular outcomes.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

The PolyIran polypill contains aspirin, atorvastatin, hydrochlorothiazide, and enalapril (or valsartan). What are the distinct pharmacological mechanisms by which these four classes of medications synergistically work to reduce the risk of acute cardiovascular events?

Key Response

This tests foundational pharmacology and pathophysiology. Aspirin provides antiplatelet effects via irreversible COX-1 inhibition, reducing TXA2. Atorvastatin lowers LDL via HMG-CoA reductase inhibition and stabilizes atherosclerotic plaques. Hydrochlorothiazide reduces blood pressure via early volume depletion and long-term vasodilation. Enalapril/valsartan inhibits the RAAS pathway, lowering blood pressure while providing independent endothelial protection and reducing adverse cardiac remodeling.

Resident

The PolyIran trial utilized a fixed-dose polypill without dose titration based on target lipid or blood pressure levels. As a resident managing a primary care panel, what are the clinical trade-offs between utilizing a fixed-dose polypill approach versus the traditional guideline-directed 'treat-to-target' strategy for cardiovascular prevention?

Key Response

Residents must balance theoretical ideals with real-world practice. The 'treat-to-target' approach allows for individualized care and optimization of hemodynamics and lipids, but often fails due to clinical inertia, polypharmacy, and poor patient adherence. The polypill sacrifices individual titration for a simpler regimen, dramatically improving medication adherence and achieving significant population-level risk reduction, which is often more impactful in primary care settings.

Fellow

The PolyIran polypill included aspirin and demonstrated a net 34% cardiovascular risk reduction in a cohort that included a large primary prevention population. How do you reconcile these findings with the ASPREE, ARRIVE, and ASCEND trials, which largely demonstrated that the bleeding risks of aspirin outweigh its benefits in modern primary prevention?

Key Response

Cardiology fellows must synthesize conflicting trial data. The discrepancy may be explained by the synergistic effect of the polypill (where concurrent blood pressure control mitigates hemorrhagic stroke risk), the specific higher-baseline-risk profile of the rural Iranian cohort compared to Western populations, and the lack of widespread baseline statin use in PolyIran, suggesting aspirin may have a favorable net clinical benefit in LMIC populations or when combined inherently with BP/lipid lowering.

Attending

Given the dramatic efficacy and cost-effectiveness of the pragmatic, cluster-randomized PolyIran trial, how should healthcare systems in resource-limited or rural settings restructure their cardiovascular prevention paradigms to prioritize broad, non-physician-led polypill distribution over individualized specialist care?

Key Response

Attendings must consider systems-based practice and resource allocation. PolyIran proves that a simplified, low-cost strategy administered by local healthcare workers (behvarzan) can overcome barriers to access and achieve outcomes that often rival complex, physician-led models. This challenges attendings to advocate for task-shifting and population-health strategies over traditional, resource-intensive, one-on-one specialist encounters for baseline prevention.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The PolyIran trial utilized a cluster-randomized design at the village level rather than individual randomization. What are the primary methodological advantages of this approach in evaluating a pragmatic public health intervention, and how must the statistical analysis adjust for the intra-cluster correlation coefficient (ICC) to prevent Type I errors?

Key Response

Researchers must understand trial design choices. Cluster randomization prevents contamination bias (where control patients in a tight-knit village might adopt the intervention or lifestyle changes). However, individuals within a cluster are not statistically independent. If researchers fail to use mixed-effects frailty models, generalized estimating equations (GEE), or adjust for the ICC, the standard errors will be artificially small, leading to inappropriately narrow confidence intervals and a high risk of falsely rejecting the null hypothesis.

Journal Editor

The PolyIran study was an open-label trial comparing a polypill to 'minimal care' rather than utilizing a placebo-controlled design. As a peer reviewer, how does this open-label design introduce performance and detection biases, and to what extent might the Hawthorne effect inflate the reported 34% relative risk reduction?

Key Response

Journal editors must rigorously assess threats to internal validity. In an open-label minimal-care design, patients receiving the daily polypill may adopt healthier lifestyles simply because the pill acts as a daily reminder of their cardiovascular health (Hawthorne effect). Furthermore, physicians might treat the control group differently (performance bias), and if outcome adjudicators are not strictly blinded, the evaluation of 'soft' endpoints like unstable angina could be skewed (detection bias).

Guideline Committee

Current ACC/AHA guidelines heavily emphasize utilizing the Pooled Cohort Equations (PCE) to risk-stratify patients before initiating primary prevention pharmacotherapy. Based on the PolyIran data demonstrating massive benefit from an age-based (over 50) polypill strategy, should international guidelines endorse a blanket, non-stratified polypill recommendation for primary prevention in low-to-middle-income countries?

Key Response

Guideline committees must evaluate applicability and global health equity. While ACC/AHA guidelines (Class I) recommend precise risk calculations requiring lab work (lipid panels) and frequent clinic visits, PolyIran demonstrates that a pragmatic, age-based threshold for a fixed-dose polypill is highly effective and feasible. Committees might consider a strong recommendation (Level of Evidence B-R) for age-based polypill strategies specifically in LMICs where the infrastructure for PCE-based individualized care is absent or cost-prohibitive.

Clinical Landscape

Noteworthy Related Trials

2016

HOPE-3 Trial

n = 12,705 · NEJM

Tested

Rosuvastatin plus Candesartan/Hydrochlorothiazide

Population

Intermediate-risk individuals without cardiovascular disease

Comparator

Dual placebo

Endpoint

Composite of cardiovascular death, nonfatal MI, or nonfatal stroke

Key result: The combined therapy of statin and blood-pressure lowering significantly reduced cardiovascular events compared to placebo.

2020

TIPS-3 Trial

n = 5,713 · NEJM

Tested

Polypill (statins, antihypertensives) plus Aspirin

Population

Individuals at intermediate or high risk of cardiovascular disease without prior events

Comparator

Placebo

Endpoint

Composite of cardiovascular death, MI, stroke, heart failure, resuscitation, or revascularization

Key result: The combination of a polypill and aspirin led to a lower risk of cardiovascular events compared to placebo.

2022

SECURE Trial

n = 2,499 · NEJM

Tested

Polypill containing aspirin, ramipril, and atorvastatin

Population

Elderly patients with a recent myocardial infarction

Comparator

Usual care

Endpoint

Composite of cardiovascular death, nonfatal type 1 MI, nonfatal stroke, or urgent revascularization

Key result: Treatment with a polypill significantly reduced major adverse cardiovascular events compared to usual care.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis